Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.
Saved in:
| Title: | Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer. |
|---|---|
| Authors: | Riaz N; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Alban TJ; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Haddad RI; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA., Saul M; Pfizer, La Jolla, CA, USA., Makarov V; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Zhu Y; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cohen EEW; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA., Ferris RL; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Chang PM; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan., Lin JC; Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan., Psyrri A; National Kapodistrian University of Athens, Athens, Greece., Parthasarathy PB; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Novaj A; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gawali M; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Hoen D; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Hamilton P; Pfizer, La Jolla, CA, USA., Silver NL; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Juric I; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Chawla D; Pfizer, La Jolla, CA, USA., Gradissimo A; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ko J; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., McGrail DJ; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA., Davis CB; Pfizer, La Jolla, CA, USA. craig.davis@pfizer.com., Lee NY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leen2@mskcc.org., Chan TA; Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA. chant2@ccf.org.; National Center for Regenerative Medicine, Cleveland, OH, USA. chant2@ccf.org. |
| Source: | Nature cancer [Nat Cancer] 2026 Jan; Vol. 7 (1), pp. 98-115. Date of Electronic Publication: 2026 Jan 02. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
